Browse

M1 macrophage-derived nanovesicles repolarize M2 macrophages for cancer treatment
암 치료를 위한 M1 대식세포에서 추출한 나노베지클에 의한 M2 대식세포의 재분화 연구

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
추연웅
Advisor
김병수
Major
공과대학 화학생물공학부
Issue Date
2018-08
Publisher
서울대학교 대학원
Description
학위논문 (석사)-- 서울대학교 대학원 : 공과대학 화학생물공학부, 2018. 8. 김병수.
Abstract
Cancer immunotherapy is a treatment that activate immune cells to induce anti-tumor immune response. Since macrophages are common immune cells in tumor microenvironment (TME), tumor-associated macrophages (TAM) are studied as a attractive target for cancer immunotherapy. Macrophages are known to have two different phenotypes
M2 macrophages release anti-inflammatory cytokines and angiogenesis factor that potentiate tumor growth. M1 macrophages release pro-inflammatory cytokines and induce anti-tumor immune response. Cancer cells release cytokines that affect TAM to polariae to M2 macrophages. Thus, repolarazation of M2 TAM to M1 macrophages may be promising immunotherapy.

Exosomes are known as nanocarrier that can induce phenotype change in recipient cells. In this study, we used exosome-like nanovesicles derived from M1 macrophages (M1NV) to repolarize M2 macrophages to M1 macrophages. M1NV treatment to M2 macrophage showed successful upregulation of M1 marker mRNA expression, protein expression, and cytokines expression in M2 macrophages. Thus, our study indicates M1NV treatment repolarize M2 TAM to M1 macrophages for cancer immunotherapy.
Language
English
URI
http://hdl.handle.net/10371/143965
Files in This Item:
Appears in Collections:
College of Engineering/Engineering Practice School (공과대학/대학원)Dept. of Chemical and Biological Engineering (화학생물공학부)Theses (Master's Degree_화학생물공학부)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse